专利检索 ap:("Baxter International Inc" OR "Baxter Healthcare SA") AND inv:"SZABO, Christina" 第 1 页

1.

发明公开
NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE AND USE OF NMR ANALYSES OF THE SAME 审中-公开
标题翻译：亲核催化剂结合和使用肟的NMR分析可知：

公开(公告)号：EP2849794A1

公开(公告)日：2015-03-25

申请号：EP13724491.9

申请日：2013-05-16

申请人： Baxter International Inc , Baxter Healthcare SA

发明人： RAY, G., Joseph , ZHANG, Zhenqing , SZABO, Christina , SIEKMANN, Juergen , SCHEINECKER, Richard , HAIDER, Stefan , ROTTENSTEINER, Hanspeter , KOSMA, Paul

IPC分类号： A61K47/48

CPC分类号： A61K47/61 , A61K47/60

摘要： The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation and analyzing the conjugation using 2D NMR analysis. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.

2.

发明公开
METHODS AND SYSTEMS FOR SCREENING COMPOSITIONS COMPRISING NON-ANTICOAGULANT SULFATED POLYSACCHARIDES 审中-公开
标题翻译：为筛选组合物的方法和系统不GERIN完硫酸多糖

公开(公告)号：EP2885642A1

公开(公告)日：2015-06-24

申请号：EP13829280.0

申请日：2013-08-12

申请人： Baxter International Inc , Baxter Healthcare SA

发明人： DOCKAL, Michael , SCHEIFLINGER, Friedrich , ZHANG, Zhenqing , TILL, Susanne , KNAPPE, Sabine , SZABO, Christina

IPC分类号： G01N33/86 , G01N33/50 , G01N33/48

CPC分类号： G01N33/86

摘要： Aspects of the invention include methods for identifying one or more NASP (non-anticoagulant sulfated polysaccharide) compositions that are suitable for treating a subject having a blood coagulation disorder. In practicing methods according to certain embodiments, NASP compositions are evaluated by determining the coagulation activity and chemical makeup of the NASP composition and the molecular structure of the NASP. Systems for practicing methods of the invention as well as compositions suitable for treating a subject having a blood coagulation disorder are also described.